Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (161-170 of 180) with videos related to

Pageof 18
Sort By:
Transplantation and Cellular Therapy|September 19, 2021
Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Leonard C Alsfeld, et al.
The Lancet. Haematology|November 4, 2018
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trialUday R Popat, Rohtesh S Mehta, Roland Bassett, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Nature Medicine|January 5, 2024
Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Blood Cancer Discovery|October 27, 2025
CD70-Targeting CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma ModelsPaul Lin, Sunil Acharya, Francia Reyes-Silva, et al.
Cell Reports|July 16, 2021
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapyRafet Basar, Nadima Uprety, Emily Ensley, et al.
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Bone Marrow Transplantation|February 15, 2024
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxisAlexandre E Malek, Taha Al-Juhaishi, Denái R Milton, et al.
Nature Medicine|April 4, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Pageof 18

Showing results (161-170 of 180) with videos related to

Sort By:
Pageof 18
Transplantation and Cellular Therapy|September 19, 2021
Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Leonard C Alsfeld, et al.
The Lancet. Haematology|November 4, 2018
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trialUday R Popat, Rohtesh S Mehta, Roland Bassett, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Nature Medicine|January 5, 2024
Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Blood Cancer Discovery|October 27, 2025
CD70-Targeting CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma ModelsPaul Lin, Sunil Acharya, Francia Reyes-Silva, et al.
Cell Reports|July 16, 2021
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapyRafet Basar, Nadima Uprety, Emily Ensley, et al.
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Bone Marrow Transplantation|February 15, 2024
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxisAlexandre E Malek, Taha Al-Juhaishi, Denái R Milton, et al.
Nature Medicine|April 4, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Pageof 18